Neurosense Therapeutics is trading 5.4% lower at $3.30 in pre-market, with no specific overnight catalyst established. - The company announced October 13 that its Nasdaq hearing is scheduled for November 10; trading continues while the appeal is pending. - A $35 million market-value listing deficiency remains. - Roth Capital downgraded the stock to Neutral, citing a delayed PrimeC Phase 3 start; neither this downgrade nor the hearing update is confirmed as the cause of the pre-market decline.